Showing results (401-410 of 1,188) with videos related to
Sort By:
Pageof 119
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 12, 2010
The combination of a histone deacetylase inhibitor with the Bcl-2 homology domain-3 mimetic GX15-070 has synergistic antileukemia activity by activating both apoptosis and autophagyYue Wei, Tapan Kadia, Weigang Tong, et al.Clinical Lymphoma, Myeloma & Leukemia|August 24, 2013
Decitabine can be safely reduced after achievement of best objective response in patients with myelodysplastic syndromeHady Ghanem, A Megan Cornelison, Guillermo Garcia-Manero, et al.Cancer|October 2, 2010
Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia: a randomized trial of frontline high-dose imatinib mesylate with or without pegylated interferon alpha-2b and granulocyte-macrophage colony-stimulating factorJorge Cortes, Alfonso Quintás-Cardama, Dan Jones, et al.Cancer Medicine|September 11, 2019
Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United StatesIman Abou Dalle, Hagop Kantarjian, Jan Burger, et al.Cancer|February 8, 2006
Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposalJorge E Cortes, Moshe Talpaz, Susan O'Brien, et al.The Journal of Infection|June 18, 2025
Blastemia portrays a poor prognosis in acute leukemia patients with invasive pulmonary aspergillosisSung-Yeon Cho, Sebastian Wurster, Ying Jiang, et al.Genes, Chromosomes & Cancer|November 13, 2009
Modeling interactions between leukemia-specific chromosomal changes, somatic mutations, and gene expression patterns during progression of core-binding factor leukemiasDan Jones, Hui Yao, Angela Romans, et al.Cancer|September 16, 2003
Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemiaJorge Cortes, Moshe Talpaz, Susan O'Brien, et al.Cancer|September 13, 2007
PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 studyElias Jabbour, Hagop Kantarjian, Jorge Cortes, et al.Nature Immunology|April 22, 2020
Adaptive response to inflammation contributes to sustained myelopoiesis and confers a competitive advantage in myelodysplastic syndrome HSCsTomoya Muto, Callum S Walker, Kwangmin Choi, et al.Pageof 119